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Abstract
Introduction The aim of this study was to investigate the
magnetic resonance imaging (MRI) features of bone disease in
the arthritis mutilans (AM) form of psoriatic arthritis (PsA).
Methods Twenty-eight patients with erosive PsA were enrolled
(median disease duration of 14 years). Using x-rays of both
hands and feet, 11 patients were classified as AM and 17 as
non-AM (erosive psoriatic arthritis without bone lysis)by two
observers. MRI scans (1.5T) of the dominant hand (wrist and
fingers scanned separately) were obtained using standard
contrast-enhanced T1-weighted and fat-saturated T2-weighted
sequences. Scans were scored separately by two readers for
bone erosion, oedema and proliferation using a PsA MRI scoring
system. X-rays were scored for erosions and joint space
narrowing.
Results On MRI, 1013 bones were scored by both readers.
Reliability for scoring erosions and bone oedema was high
(intraclass correlation coefficients = 0.80 and 0.77 respectively)
but only fair for bone proliferation (intraclass correlation
coefficient = 0.42). MRI erosion scores were higher in AM
patients (53.0 versus 15.0, p = 0.004) as were bone oedema
and proliferation scores (14.7 versus 10.0, p = 0.056 and 3.6
versus 0.7, p = 0.003 respectively). MRI bone oedema scores
correlated with MRI erosion scores and X-ray erosion and joint
space narrowing scores (r = 0.65, p = 0.0002 for all) but not the
disease activity score 28-C reactive protein (DAS28CRP) or pain
scores.
Conclusions In this patient group with PsA, MRI bone oedema,
erosion and proliferation were all more severe in the AM-form.
Bone oedema scores did not correlate with disease activity
measures but were closely associated with X-ray joint damage
scores. These results suggest that MRI bone oedema may be a
pre-erosive feature and that bone damage may not be coupled
with joint inflammation in PsA.
AM: arthritis mutilans; CI: confidence interval; CRP: C-reactive protein; DAS: disease activity score; DEXA: dual energy XRay absorptiometry; DIP: 
distal interphalangeal; ESR: erythrocyte sedimentation rate; Gd-DTPA: gadolinium diethylenetriamine pentaacetic acid; HAQ: Health Assessment 
Questionnaire; MCP: metacarpophalangeal; MRI: magnetic resonance imaging; non-AM: erosive psoriatic arthritis without bone lysis; OMERACT: 
Outcome Measures in Rheumatology Clinical Trials; PAMRIS: Psoriatic arthritis MRI scoring system; PASI: Psoriasis Area and Severity Index; PF-SF-
36: Physical Function component of the Short form-36; PIP: proximal interphalangeal; PNSS: Psoriasis Nail Severity Score; PsA: psoriatic arthritis; 
RA: rheumatoid arthritis; RAMRIS: Rheumatoid Arthritis Magnetic Resonance Imaging Scoring system; PsAMRIS: Psoriatic Arthritis Magnetic Reso-
nance Imaging Scoring system; SpA: spondyloarthropathies; STIR: short tau inversion recovery; TNF: tumour necrosis factor; 3D VIBE: three-dimen-
sional volumetric interpolated breath-hold examination; XR: plain radiography.Arthritis Research & Therapy    Vol 11 No 1    Tan et al.
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Introduction
Arthritis mutilans (AM) is the most severe and destructive of
the five clinical presentations of psoriatic arthritis (PsA) as
defined by Moll and Wright [1]. It is characterised by severe
radiographic erosion with bony osteolysis, often resulting in
digital shortening and the 'main en lorgnette' (opera-glass
hand) deformity [2]. Bone proliferation and arthrodesis may
coexist with erosion in PsA and both forms of bone disease
have been described in AM [3]. Magnetic resonance imaging
(MRI) can reveal more information about bone pathology in
inflammatory arthritis than conventional radiography (XR) as it
is a multiplanar technique with the capacity to depict bone ero-
sion and proliferation using three-dimensional imaging. MRI is
the only imaging modality capable of revealing bone oedema,
which in rheumatoid arthritis (RA) has been shown to be a pre-
erosive change and associated with osteitis [4-6]. MRI bone
oedema has also been described in PsA [7-10] where it may
be diaphyseal as well as subchondral [8] and is responsive to
anti-tumour necrosis factor (TNF) therapy [10]. In this study we
investigated the characteristics of bone disease in erosive PsA
using XR, contrast-enhanced MRI scanning and dual energy
X-Ray absorptiometry (DEXA). We sought to determine
whether the AM form differs from non-AM (erosive psoriatic
arthritis without bone lysis) PsA using these modalities, specif-
ically concentrating on MRI bone oedema in view of its poten-
tial role in the genesis of bone erosion.
Materials and methods
Patients and clinical assessments
With the approval of the New Zealand Multiregion Ethics
Committee, 28 patients with PsA (as defined by Vasey and
Espinzoa modified by Taylor and colleagues [11]) were
recruited from Auckland, Rotorua and Wellington in New Zea-
land from 2005 to 2007. These patients were enrolled as part
of a longitudinal study investigating the effects of zoledronic
acid on the progression of bone erosions in PsA (the
zoledronic acid in psoriatic arthritis or ZAPA study), but results
presented here pertain only to baseline findings in these
patients, before administration of the study drug or placebo.
All patients gave informed consent according to the require-
ments of the New Zealand Multiregion Ethics Committee.
Enrolment criteria included the presence of peripheral ero-
sions on XR confirmed by a radiologist. A total of 17 males and
11 females were enrolled and all underwent clinical assess-
ments including collection of demographic data, as well as dis-
ease activity scores (DAS) obtained from history, examination
and laboratory investigations including duration of early morn-
ing stiffness, swollen (n = 76) and tender (n = 78) joint counts,
visual analogue scores for pain and overall well-being, patient
and physician global assessments, erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP). DAS-28CRP (four var-
iable) and DAS-28ESR (four variable) scores were computed to
indicate overall disease activity [12]. Assessments of func-
tional disability were also obtained using the Health Assess-
ment Questionnaire (HAQ) score [13], which has been used
to assess functional limitations in PsA [14] and the Physical
Function component of the Short form-36 (PF-SF-36) score
[15]. Severity of psoriasis was assessed using the Psoriasis
Area and Severity Index (PASI) [16] and the Psoriasis Nail
Severity Score (PNSS) [17] was also used.
Radiography
Plain XRs of the hands, feet and sacroiliac joints were
obtained at enrolment. XRs were scored by a radiologist and
a rheumatologist (QR and ND) for erosions and joint space
narrowing according to the Sharp van der Heijde score modi-
fied for use in PsA [18]. Sacroiliitis was scored as present or
absent by another clinical radiologist.
Radiographic definition of arthritis mutilans
Patients were categorised as having AM or non-AM PsA on
the basis of XR features in the peripheral joints, using the def-
inition from Marsal and colleagues [19], which requires com-
plete erosion of bone on both sides of the joint(s). This was
performed by two readers (WT and QR) who reviewed digi-
tised films separately and, where there was disagreement by
consensus, blinded to clinical and MRI findings.
Clinical definition of arthritis mutilans
Clinical digitised photographs of the hands and feet were
obtained in 25 of the 28 patients. These were examined by a
rheumatologist (ND) blinded to the results of radiography and
MRI. Patients were classified as AM or non-AM according to
the presence of digital shortening in the fingers or toes.
Patients were also classified separately by their referring phy-
sicians as AM or non-AM.
MRI scans
MRI scans of the wrist (distal radius and ulna, carpal bones
and metacarpal bases 2 to 5) and fingers (metacarpals proxi-
mal to bases, metacarpophalangeal (MCP) joints, proximal
phalanges, proximal interphalangeal (PIP) joints, middle
phalanges, distal interphalangeal (DIP) joints, distal
phalanges) of the dominant hand were obtained using a Sie-
mens Magnetom Avanto 1.5 Tesla (T) scanner (Siemens, Pen-
rose, Auckland New Zealand) with a dedicated wrist coil
(small field of view at 11 cm for optimal signal-to-noise ratio).
Details of sequences and acquisitions are shown in Table 1.
The sequence of imaging was as follows: unenhanced imag-
ing of the fingers; the patient was repositioned so that the
wrist was within the coil; unenhanced imaging of the wrist;
contrast injection; enhanced imaging of the wrist; the patient
was repositioned so that the fingers were within the coil; and
then enhanced imaging of the fingers was performed. Bone
oedema was investigated using short tau inversion recovery
(STIR) sequences, whereas bone erosion and bone prolifera-
tion were assessed on axial and coronal T1-weighted
sequences. For all parameters a water-excitation volumetric
interpolated breath-hold examination (3D VIBE) sequence (aAvailable online http://arthritis-research.com/content/11/1/R2
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gradient echo 3D T1-weighted sequence) was used as a sup-
plement. This sequence was obtained after intravenous admin-
istration of the contrast agent, gadolinium diethylenetriamine
pentaacetic acid (Gd-DTPA).
Scans were scored separately by two trained readers (MØ
and AD) for bone erosion and bone oedema using Rheuma-
toid Arthritis Magnetic Resonance Imaging Scoring system
(RAMRIS) [20] criteria modified for PsA (Psoriatic Arthritis
Magnetic Resonance Imaging Scoring System, PsAMRIS)
[21]. The following bones were scored for erosion (0 to 10)
and bone oedema (0 to 3): hamate, capitate, trapezoid, trape-
zium, triquetrum, pisiform, lunate, scaphoid, distal ulna, distal
radius, bases of metacarpals (2 to 5), MCP joint region (2 to 5
proximal and distal to the joint), PIP joint region (2 to 5 proximal
and distal to the joint) and DIP joint region, (2 to 5 proximal and
distal to the joint). Bone proliferation was also scored at each
bone site as present or absent (0 or 1). Scores were averaged
across readers to provide one data set for this analysis. Data
from the fingers were also analysed on the basis of individual
MCP, PIP and DIP joints. A mean score for both readers was
obtained at each joint for erosions, bone oedema and bone
proliferation: erosions were scored (0 to 20), bone oedema (0
to 6) and bone proliferation (0 to 2) to include bone involve-
ment on each side of the joint.
Bone densitometry
Bone densitometry was performed at L1 to L4 and at the fem-
oral neck using a Lunar Expert dual energy absorptiometer
(GE Lunar, Madison, WI). Results were expressed as T scores
representing the number of standard deviations below the
average for a young adult at peak bone density. For the pur-
poses of this analysis T scores for L1 to L4 were averaged.
Statistical analysis
Intraclass correlation coefficients (ICC) with 95% confidence
intervals (CI) were used to assess the interobserver reliability
of scoring of XR and MRI features. Mann Whitney U tests and
Chi squared tests were used to test differences between AM
and non-AM groups in terms of demographics, disease activ-
ity, XR measures and MRI measures. Medians with ranges or
interquartile ranges and percentages were used to describe
these differences. Spearman's correlations were used to
assess the association between MRI bone oedema scores
and other measures.
Results
In total, 11 of the 28 patients were classified by the XR defini-
tion as AM and 17 as non-AM. In six cases, opinions of the XR
readers differed and these were re-examined and a consensus
reached. Of the 11 patients with XR-AM, seven fitted the clin-
ical definition of AM with digital shortening (Figure 1). The fol-
lowing analysis has used the XR definition of AM. Table 2
shows demographic details for the AM group compared with
the non-AM group, as well as their medications, DAS and func-
tional measures.
Interobserver reliability for scoring XR and MRI features
XR features of erosion and joint space narrowing were
assessed at the hands and feet by two observers (ND and
QR). Interobserver reliability was high for each with ICCs and
95% confidence intervals (CI) as follows: erosions 0.79 (0.42
to 0.83), joint space narrowing 0.90 (0.80 to 0.95) and when
combined for a modified total Sharp score (including DIP
joints) 0.86 (0.74 to 0.93).
Table 1
MRI sequences and acquisitions
WRIST FOV SLICE TR TE MATRIX
AXIAL T1 110 mm 3.0 mm 473 ms 19 ms 192 × 320
AXIAL STIR 110 mm 3.0 mm 4500 ms 59 ms 192 × 256
CORONAL T1 110 mm 3.0 mm 453 ms 19 ms 224 × 320
CORONAL STIR 110 mm 3.0 mm 4600 ms 62 ms 192 × 256
VIBE (post-contrast) 110 mm 0.6 mm 16.4 ms 6.83 ms 192 × 192
FINGERS
CORONAL T1 110 mm 3.0 mm 453 ms 19 ms 224 × 320
AXIAL T1 110 mm 3.0 mm 633 ms 19 ms 230 × 320
SAGITTAL STIR 110 mm 3.0 mm 3140 ms 54 ms 192 × 256
VIBE (post-contrast) 110 mm 0.6 mm 16.4 ms 6.83 ms 192 × 192
FOV = field of view, STIR = short tau inversion recovery, T1 = T1-weighted, TR = repetition time, TE = echo time, VIBE = volumetric interpolated 
breath-hold examination.Arthritis Research & Therapy    Vol 11 No 1    Tan et al.
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For the MRI analysis, a total of 1013 bones at the dominant
wrist and fingers were scored for bone erosion, oedema and
proliferation by two readers (MØ and AD) working separately
in two different institutions. Reliability for scoring MRI erosions
and bone oedema was high: 0.80 (0.62 to 0.90) and 0.77
(0.57 to 0.88) respectively. It was lower for bone proliferation:
0.42 (0.07 to 0.67).
Clinical disease activity in AM versus non-AM patients
There was no difference between AM and non-AM groups in
terms of DAS with respect to inflammatory markers (ESR and
CRP), clinical evidence of joint inflammation (pain score, ten-
der and swollen joints counts), joint function (HAQ score and
PF-SF-36) or indicators of the severity of skin and nail disease
(PASI and nail severity score) (Table 2).
MRI and XR scores in AM vs non-AM patients
MRI scans of the dominant fingers (including DIP joints) and
wrist were obtained in all patients. Table 3 summarises the
data for the AM group versus the non-AM group. As expected,
XR and MRI erosion scores (median) were higher in the AM
group (89.8 versus 21.0, p = 0.001 and 53.0 versus 15.0, p
= 0.004, respectively). When the analysis was performed on a
joint-by-joint basis at the fingers, AM patients were found to
have higher scores for erosions and bone proliferation (Table
3). MRI bone oedema scores were also higher in the AM group
(14.7 versus 10.0, p = 0.056) (Figure 2) as were bone prolif-
eration scores (3.6 versus 0.7, p = 0.003). Of the 304 bones
where erosions were scored, 131 (43.1%) also scored posi-
tive for bone oedema. There was no difference between AM
and non-AM groups in the frequency of sacroiliitis or T scores
from bone densitometry (lumbar spine or hip).
Correlations between MRI, XR and clinical scores
The MRI erosion and bone oedema scores correlated strongly
with the XR erosion score (r = 0.709, p < 0.0001 and r = 0.65,
p = 0.0002, respectively). The MRI bone oedema score also
correlated strongly with the MRI erosion score (r = 0.66, p =
0.0002) and XR total joint space narrowing score (r = 0.65, p
= 0.0002) (Figure 3). Interestingly, the MRI bone oedema
score did not correlate with clinical indicators of disease activ-
ity such as the DAS28CRP or pain scores (r = 0.18, p = 0.39
and r = 0.03, p = 0.87, respectively). Both readers scored dia-
physeal bone oedema as present in six bones in four patients
(one AM and three non-AM). An example is shown in Figure 4
where diaphyseal bone oedema was revealed on both STIR
and VIBE sequences.
Discussion
The MRI features of PsA have only recently begun to be
explored [22]. This disease differs radiographically from RA in
that bone erosion and bone proliferation are both recognised
(and sometimes coexist in the same joint), although the char-
acteristic features of spondyloarthropathies (SpA), such as
sacroiliiitis and enthesitis, may also occur [23]. MRI reflects
these findings and provides additional information through its
capacity to image synovitis, tenosynovitis, dactylitis and also
bone oedema, which has been described at subchondral,
entheseal and diaphyseal locations [7]. AM represents the
most severe end of the spectrum as far as bone disease is
concerned in PsA with extreme bony lysis and 'pencil-in-cup'
deformities resulting in digital shortening and the main en lor-
gnette deformity. In this study we have investigated bone dis-
ease in patients with AM and non-AM forms of erosive PsA
using three imaging modalities; contrast-enhanced MRI, XR
and DEXA. We defined AM in two ways using information from
several sources and chose to use the radiographic definition
of Marsal and colleagues [19] as verified by two observers.
Our first concern was that this did not completely coincide
with the clinical definition from digital photographs, which
were assessed separately. On further investigation it became
apparent that those patients fitting the clinical definition
formed a subset of those defined radiographically.
For the purposes of this study we used the Psoriatic Arthritis
Magnetic Resonance Imaging Scoring system (PsAMRIS)
currently being developed and validated by an ongoing Out-
come Measures in Rheumatology Clinical Trials (OMERACT)-
based project [21]. This involved scoring bone erosion,
oedema and proliferation at the sites dictated by the RAMRIS
Figure 1
A patient with arthritis mutilans with digital shortening A patient with arthritis mutilans with digital shortening. (a) Clinical photograph. (b) Radiograph of the hands.Available online http://arthritis-research.com/content/11/1/R2
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Table 2
Demographics, medications and disease activity in AM and non-AM patients
Clinical features AM*(N = 11) Non AM (N = 17) p value
Median (range) Median (range)
Age (years) 52 (36 to 63) 50 (20 to 63) 0.56
Duration of PsA (years) 12 (5 to 35) 10 (5 to 25) 0.51
Duration of psoriasis (years) 22 (11 to 49) 20 (5 to 50) 0.24
Weight (kg) mean (range) 78 (65 to 107) 83 (68 to 111) 0.42
Female:Male 3:8 8:9 0.44
Ethnicity: European 91% 88% 0.94
Medications Number (%) Number (%)
Methotrexate 4 (36%) 11 (65%)
NSAIDs 7 (64%) 10 (10%)
Prednisone 5 to 20 mg/day 2 (18%) 2 (12%)
Sulphasalazine 2 to 3 g/day 3 (28%) 5 (29%)
Azathioprine 150 mg/day 0 1 (6%)
Hydroxychloroquine 400 mg/day 0 1 (6%)
Leflunomide 20 mg/day 1 (9%) 0
Cyclosporin 100 mg/day 0 1 (6%)
Disease activity Median (range) Median (range)
Tender joint count 17 (1 to 40) 11 (4 to 51) 0.98
Swollen joint count 6 (0 to 33) 4 (0 to 9) 0.20
Pain score 35 (16 to 78) 45 (6 to 82) 0.47
HAQ score (n = 27) 1.1 (0 to 3.5) 0.7 (0 to 3) 0.26
PF-SF-36 52.5 (5 to 85) 65 (10 to 90) 0.39
ESR (mm/hour) 14 (1 to 43) 13 (2 to 86) 0.61
CRP (mg/litre) (n = 25) 11.6 (3 to 59) 4.9 (< 1 to 46) 0.26
DAS28-CRP (n = 23) 3.91 (2.6 to 5.7) 4.2 (2.3 to 6.2) 0.64
DAS28-ESR (n = 28) 4.2 (1.7 to 6.1) 4.0 (1.9 to 6.9) 0.61
Psoriatic nail severity score 11 (0 to 47) 8 (0 to 22) 0.19
PASI (n = 26) 0.6 (0 to 12) 1.8 (0 to 10.3) 0.84
AM = arthritis mutilans, CRP = c-reactive protein, DAS28 – CRP = Disease Activity Score (28 swollen and tender joints, CRP, General Health 
VAS), DAS28 – ESR = Disease Activity Score (28 swollen and tender joints, ESR, General Health VAS), ESR = Erythrocyte Sedimentation Rate, 
HAQ = Health Assessment Questionnaire, non-AM = non-arthritis mutilans, NSAID = nonsteroidal anti-inflammatory drugs, PASI = Psoriasis Area 
and Severity Index, PF-SF-36 = Physical Function component of the Short Form 36 Questionnaire, PsA = psoriatic arthritis.Arthritis Research & Therapy    Vol 11 No 1    Tan et al.
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system [20] with the addition of the PIP and DIP joints. These
data were obtained from review of a very large number of bony
regions (1013) by two readers working completely independ-
ently in different institutions. A high degree of inter-reader reli-
ability was demonstrated both for bone erosions and bone
oedema (ICCs of 0.8 and 0.77, respectively), despite the fact
that many patients had extremely advanced and deforming dis-
ease, making many regions difficult to assess. Bone prolifera-
tion data are also presented although the interobserver
reliability was only moderate (ICC = 0.42), possibly because
of the difficulty in recognising proliferation when it appears
adjacent to regions of severe erosion. In another group of PsA
patients with relatively early disease, the ICC for the bone pro-
liferation component of PsAMRIS was much higher at 0.91
(unpublished data) and this emphasises the heterogeneity of
PsA and the fact that this system for scoring disease features
may perform differently in different patient groups.
As expected, the AM group had higher XR erosion and joint
space narrowing scores at the hands and feet than non-AM
patients and this was also true for MRI erosions at the domi-
nant fingers and wrist. A major new finding was that MRI bone
oedema was also higher in the AM group. Interestingly, bone
oedema scores were highly correlated with MRI and XR ero-
sion and joint space narrowing scores, suggesting that this
feature occurs in those with more severe, damaging bone dis-
ease. We did not find an association with functional scores,
pain or disease activity and this is consistent with observations
in other SpA [24,25] but differs from findings in RA, where
there is good evidence that bone oedema is an inflammatory
indicator that correlates with CRP in early and established dis-
ease [4,26]. Clinical studies have also suggested that RA and
PsA differ in terms of the CRP and other markers of disease
activity [14,27]. Buskila and coleagues noted that PsA
patients reported less tenderness of inflamed joints than RA
patients and concluded that the DAS28 may not adequately
reflect the burden of inflammation in PsA for this reason and
also because it excludes the DIP and foot joints [28].
This study has revealed a number of negative findings. We did
not find a particular association between AM and sacroiliitis as
has been noted previously [19]. This is probably because we
enrolled a relatively homogeneous group of patients with ero-
sive PsA only, whereas studies that have found sacroiliitis to
be more common in the AM form have used a broader group
of PsA patients with erosive and non-erosive disease as their
denominator. Another negative finding from this study was that
bone density measurements at the femoral neck and lumbar
spine did not differ between the AM and non-AM groups. In
RA, those patients with the most active, erosive disease tend
to be those with the most severe osteopenia, both periarticular
and generalised [29]. Periarticular osteopenia is not a feature
of PsA [30] but one study has shown that bone mineral density
at the spine in PsA patients is lower than normal controls [31].
Grisar and colleagues found evidence that markers of bone
resorption were increased in PsA patients and correlated with
the acute phase response [32], but they did not examine the
association between BMD and CRP which was not significant
in our group.
Conclusion
To the best of our knowledge, we have presented the first MRI
study investigating the AM variant of PsA. We confirmed that
MRI and XR joint damage (erosion) and proliferation scores
were higher in the AM group than in those with non-AM ero-
sive PsA, despite there being no evidence of greater disease
activity in terms of clinical scores (skin or joint) or inflammatory
markers. Interestingly, the MRI bone oedema score was also
higher in the AM group and correlated strongly with erosion
and joint space narrowing scores. These data suggest that
MRI bone oedema could be a forerunner of articular damage
in PsA and may be a useful biomarker to indicate aggressive
disease. Follow-up of this group is planned to explore the evo-
lution of these changes over time.
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Table 3
MRI, XR and bone densitometry in AM vs non-AM erosive PsA
MRI (dominant wrist and fingers) AM non-AM p value
Bone erosion score (PAMRIS) 53.0* (28 to 125) 15.0 (3 to 22) 0.004
MCPs bone erosion** 1.8 (0.4 to 16.3) 1.0 (0 to 4) 0.045
PIPs bone erosion 2.8 (0 to 20) 0.4 (0 to 3.4) 0.036
DIPs bone erosion 1.3 (0 to 8.8) 0.0 (0 to 3.4) 0.018
Bone oedema score (PAMRIS) 14.7 (8.3 to 19.5) 10.0 (2.0 to 12.5) 0.056
MCPs bone oedema 0.0 (0 to 3) 0.0 (0 to 2.3) 0.71
PIPs bone oedema 0.0 (0 to 3.8) 0.0 (0 to 1.5) 0.74
DIPs bone oedema 0.0 (0 to 4) 0.0 (0 to 2.8) 0.74
Bone proliferation score (PAMRIS) 3.6 (2.2 to 5.0) 0.7 (0.2 to 2.1) 0.003
MCPs bone proliferation 0.3 (0 to 1) 0.0 (0 to 0.8) 0.037
PIPs bone proliferation 0.3 (0 to 0.9) 0.0 (0 to 0.5) 0.13
DIPs bone proliferation 0.3 (0 to 0.6) 0.0 (0 to 1.0) 0.021
XR of hands and feet
XR erosion score 89.8 (69.0 to 104.3) 21.0 (6.0 to 35.0) 0.001
XR narrowing 5.0 (57.0 to 108.3) 16.5 (4.5 to 28.0) 0.002
Sacroiliitis (No. %) 3 (27%) 6 (35%) 0.98
Bone densitometry
T score L1 -4 0.7 (- 0.1 to 4.8) -0.1 (-1.6 to 2.8) 0.13
T score total femur -0.4 (-1.8 to 1.3) -0.3 (-2.1 to 1.3) 0.88
*Median + interquartile range shown
**score per joint; median (range)
AM = arthritis mutilans; DIP = distal interphalangeal; MCP = metacarpophalangeal; MRI = magnetic resonance imaging; non-AM = erosive 
psoriatic arthritis without bone lysis; PAMRIS = Psoriatic arthritis MRI scoring system; PIP = proximal interphalangeal; PsA = psoriatic arthritis; XR 
= plain radiography.
Figure 3
Scatter plots showing correlations Scatter plots showing correlations. Correlation seen between (a) magnetic resonance imaging (MRI) bone oedema score and plain radiography 
(XR) erosion score (r = 0.65, p = 0.0002); (b) MRI bone oedema and MRI erosion score (r = 0.66, p = 0.0002); and (c) MRI bone oedema score 
and XR joint space narrowing score (r = 0.65, p = 0.0002).Arthritis Research & Therapy    Vol 11 No 1    Tan et al.
Page 8 of 9
(page number not for citation purposes)
for the MRI scans and assisted in manuscript preparation. ND
assisted in patient recruitment, was a reader for the X-rays and
assisted in manuscript preparation. ML assisted in patient
recruitment and participated in data analysis. QR was a reader
for the X-rays and assisted in manuscript preparation. ER pro-
vided statistical advice and assisted in data analysis and man-
uscript preparation. WJT assisted in patient recruitment and
manuscript preparation. PBJ participated in the design of the
study and assisted in patient recruitment. KP assisted in
patient recruitment and participated in data entry. JL partici-
pated in data entry and analysis. FMM conceived of the study
and coordinated patient recruitment, data entry, data analysis
and preparation of the manuscript.
Acknowledgements
We wish to acknowledge the contribution of Shelley Park and Sandra 
Winsor from the Centre for Advanced MRI. We also wish to thank Mr 
Steven Dakin for assistance with preparation of the images. Supported 
by grants from the Auckland Medical Research Foundation, The Auck-
land Regional Rheumatology Research Trust and the University of Auck-
land (funded studentship for YMT). Partial support from an investigator-
initiated grant from Novartis.
References
1. Moll JM, Wright V: Psoriatic arthritis.  Semin Arthritis Rheum
1973, 3:55-78.
2. Eisenstadt HB, Eggers GW: Arthritis mutilans.  J Bone Joint
Surg Am 1955, 37-A:337-346.
3. O'Neill TW, Evison G, Bhalla AK: Pseudoarthroplastic' hand in
arthritis mutilans.  Br J Rheumatol 1992, 31:559-560.
4. McQueen FM, Benton N, Perry D, Crabbe J, Robinson E, Yeoman
S, McLean L, Stewart N: Bone edema scored on magnetic res-
onance imaging scans of the dominant carpus at presentation
predicts radiographic joint damage of the hands and feet six
years later in patients with rheumatoid arthritis.  Arthritis
Rheum 2003, 48:1814-1827.
5. Jimenez-Boj E, Nöbauer-Huhmann I, Hanslik-Schnabel F, Dorotka
R, Wanivenhaus A, Kainberger F, Trattnig S, Axmann R, Tsuji W,
Hermann S, Smolen J, Schett G: Bone erosions and bone mar-
row edema as defined by magnetic resonance imaging reflect
true bone marrow inflammation in rheumatoid arthritis.  Arthri-
tis Rheum 2007, 56:1118-1124.
6. McQueen FM, Gao A, Østergaard M, King A, Shalley G, Robinson
E, Doyle A, Clark B, Dalbeth N: High grade MRI bone oedema is
common within the surgical field in rheumatoid arthritis
patients undergoing joint replacement and is associated with
osteitis in subchondral bone.  Ann Rheum Dis 2007,
66:1581-1587.
7. Healy PJ, Groves C, Chandramohan M, Helliwell PS: MRI changes
in psoriatic dactylitis – extent of pathology, relationship to ten-
derness and correlation with clinical indices.  Rheumatology
(Oxford) 2008, 47:92-95.
8. Narvaez J, Narvaez JA, Nolla JM, J V: Comparative study of MR
imaging findings in wrist and hands in early psoriatic arthritis
and rheumatoid arthritis.  Arthritis Rheum 2007, 56:S281.
9. Giovagnoni A, Grassi W, Terilli F, Blasetti P, Paci E, Ercolani P,
Cervini C: MRI of the hand in psoriatic and rheumatical arthri-
tis.  Eur Radiol 1995, 5:590-595.
10. Marzo-Ortega H, McGonagle D, Rhodes LA, Tan ALCP, O-Connor
P, Tanner SF, Fraser A, Veale D, P E: Efficacy of infliximab on
MRI determined bone oedema in psoriatic arthritis.  Ann
Rheum Dis 2006, 66:778-781.
11. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mie-
lants H, Group CS: Classification criteria for psoriatic arthritis:
development of new criteria from a large international study.
Arthritis Rheum 2006, 54:2665-2673.
12. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, Putte LB
van de, van Riel PL: Modified disease activity scores that
include twenty-eight-joint counts. Development and validation
in a prospective longitudinal study of patients with rheumatoid
arthritis.  Arthritis Rheum 1995, 38:44-48.
13. Wolfe F, Michaud K, Pincus T: Development and validation of
the health assessment questionnaire II: a revised version of
the health assessment questionnaire.  Arthritis Rheum 2004,
50:3296-3305.
14. McHugh NJ, Balachrishnan C, Jones SM: Progression of periph-
eral joint disease in psoriatic arthritis: a 5-yr prospective study.
Rheumatology (Oxford) 2003, 42:778-783.
15. Raczek AE, Ware JE, Bjorner JB, Gandek B, Haley SM, Aaronson
NK, Apolone G, Bech P, Brazier JE, Bullinger M, Sullivan M: Com-
parison of Rasch and summated rating scales constructed
from SF-36 physical functioning items in seven countries:
results from the IQOLA Project. International Quality of Life
Assessment.  J Clin Epidemiol 1998, 51:1203-1214.
16. Fredriksson T, Pettersson U: Severe psoriasis – oral therapy
with a new retinoid.  Dermatologica 1978, 157:238-244.
17. Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R,
Wordsworth BP: Extended report: nail disease in psoriatic
arthritis-clinically important, potentially treatable and often
overlooked.  Rheumatology (Oxford) 2004, 43:790-794.
18. Heijde D van der, Kavanaugh A, Gladman DD, Antoni C, Krueger
GG, Guzzo C, Zhou B, Dooley LT, de Vlam K, Geusens P, Birbara
C, Halter D, Beutler A: Infliximab inhibits progression of radio-
graphic damage in patients with active psoriatic arthritis
through one year of treatment: Results from the induction and
maintenance psoriatic arthritis clinical trial 2.  Arthritis Rheum
2007, 56:2698-2707.
19. Marsal S, Armadans-Gil L, Martinez M, Gallardo D, Ribera A,
Lience E: Clinical, radiographic and HLA associations as mark-
ers for different patterns of psoriatic arthritis.  Rheumatology
(Oxford) 1999, 38:332-337.
20. Østergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg
B, Shnier R, O'Connor P, Klarlund M, Emery P, Genant H, Lassere
M, Edmonds J: OMERACT Rheumatoid Arthritis Magnetic Res-
onance Imaging Studies. Core set of MRI acquisitions, joint
pathology definitions, and the OMERACT RA-MRI scoring sys-
tem.  J Rheumatol 2003, 30:1385-1386.
2 1 . M c Q u e e n  F ,  L a s s e r e  M ,  B i r d  P ,  H a a v a r d s h o l m  E A ,  P e t e r f y  C ,
Conaghan PG, Ejbjerg B, Genant H, O'Connor P, Emery P, Øster-
gaard M: Developing a magnetic resonance imaging scoring
system for peripheral psoriatic arthritis.  J Rheumatol 2007,
34:859-861.
22. McQueen F, Lassere M, Østergaard M: Magnetic resonance
imaging in psoriatic arthritis: a review of the literature.  Arthritis
Res Ther 2006, 8:207.
Figure 4
Sagittal T2 weighted fat-saturated (FS) magnetic resonance imaging  (MRI) scan of the fifth finger of a patient with non-AM Sagittal T2 weighted fat-saturated (FS) magnetic resonance imag-
ing (MRI) scan of the fifth finger of a patient with non-AM. (a) Dia-
physeal bone oedema is shown (circle) and confirmed on (b) coronal 
post-contrast volumetric interpolated breath-hold examination (VIBE) 
sequence (circle).Available online http://arthritis-research.com/content/11/1/R2
Page 9 of 9
(page number not for citation purposes)
23. Rahman P, Nguyen E, Cheung C, Schentag CT, Gladman DD:
Comparison of radiological severity in psoriatic arthritis and
rheumatoid arthritis.  J Rheumatol 2001, 28:1041-1044.
24. Goh L, Suresh P, Gafoor A, Hughes P, Hickling P: Disease activ-
ity in longstanding ankylosing spondylitis – a correlation of
clinical and magnetic resonance imaging findings.  Clin Rheu-
matol 2008, 27:449-455.
25. Baraliakos X, Landewe R, Hermann KG, Listing J, Golder W,
Brandt J, Rudwaleit M, Bollow M, Sieper J, Heijde D van der, Braun
J:  Inflammation in ankylosing spondylitis: a systematic
description of the extent and frequency of acute spinal
changes using magnetic resonance imaging.  Ann Rheum Dis
2005, 64:730-734.
26. McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan
PL, McLean L: Magnetic resonance imaging of the wrist in early
rheumatoid arthritis reveals a high prevalence of erosions at
four months after symptom onset.  Ann Rheum Dis 1998,
57:350-356.
27. Daunt AO, Cox NL, Robertson JC, Cawley MI: Indices of disease
activity in psoriatic arthritis.  J R Soc Med 1987, 80:556-558.
28. Buskila D, Langevitz P, Gladman DD, Urowitz S, Smythe HA:
Patients with rheumatoid arthritis are more tender than those
with psoriatic arthritis.  J Rheumatol 1992, 19:1115-1119.
29. Hoff M, Haugeberg G, Kvien TK: Hand bone loss as an outcome
measure in established rheumatoid arthritis: 2-year observa-
tional study comparing cortical and total bone loss.  Arthritis
Res Ther 2007, 9:R81.
30. Resnick D, Niwayama J: Psoriatic arthritis.  In Diagnosis of bone
and joint disorders 3rd edition. Philadelphia: WB Saunders;
1995:1075-1101. 
31. Frediani B, Allegri A, Falsetti P, Storri L, Bisogno S, Baldi F, Filip-
poni P, Marcolongo R: Bone mineral density in patients with
psoriatic arthritis[see comment].  J Rheumatol 2001,
28:138-143.
32. Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozc-
szuk W, Spitzauer S, Grampp S, Kainberger F, Ebner W, Smolen
JS, Pietschmann P: Ankylosing spondylitis, psoriatic arthritis,
and reactive arthritis show increased bone resorption, but dif-
fer with regard to bone formation.  J Rheumatol 2002,
29:1430-1436.